STAT19h
Merck’s earnings miss focused attention on Gardasil. The real issue is Keytruda
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
FiercePharma1d
Merck halts Gardasil shipments to China, withdraws $11B sales target as demand nosedives
The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...
Should You Pick MRK Stock At $90?
Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.
Analysts Defend Merck Amid Investor Concerns Over Weak Guidance
Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of foreign exchange, ...
Merck touts 20 new ‘blockbuster’ drugs in development with $50 billion potential
Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.
Big Pharma, Bigger Bargain: Why Merck Stock Is Too Cheap To Ignore (Upgrade)
Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...
Merck beats estimates on fourth-quarter on earnings—but stock slides pre-market on tepid 2025 guidance
Merck ( MRK) reported fourth quarter and full year earnings Tuesday, in line with Wall Street estimates. The bad news: Its ...
Merck Stock Tumbles on Weak Guidance and Gardasil Sales Slump
Merck stock fell in premarket trading Tuesday after the company said sales of its blockbuster HPV vaccine, Gardasil, declined ...